Prediction of proliferative diabetic retinopathy with hemoglobin level

Archives of Ophthalmology

Volumn 127, Issue 11, 2009, Pages 1494-1499

  Conway, Baqiyyah N ^a   Miller, Rachel G ^a   Klein, Ronald ^b   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; CHOLESTEROL; DIAGNOSTIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; INCIDENCE; METABOLISM; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE;

ADULT; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; INCIDENCE; LIPOPROTEINS; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; YOUNG ADULT;

EID: 70449723109     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.274     Document Type: Article

References (46)

1. Dintenfass L. Blood viscosity factors in severe nondiabetic and diabetic retinopathy. Biorheology. 1977;14(4):151-157. (Pubitemid 8187834)
2. Mohanram A, Zhang Z, Shahinfar S, Keane W, Brenner BM, Toto RD. Anaemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66(3):1131-1138. (Pubitemid 39121019)
3. Conway B, Fried L, Costacou T, Orchard T. Hematocrit predicts end stage renal disease (ESRD) and non-ESRD mortality in type 1 diabetes with overt nephropathy. Diabetes. 2005;54(S1):A551.
4. Davis MD, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest Ophthalmol Vis Sci. 1998;39(2):233-252. (Pubitemid 28093859)
5. Yoshimoto M, Matsumoto S. Changes in diabetic retinopathy and visual acuity in patients with end-stage diabetic nephropathy after the introduction of hemodialysis [in Japanese]. Nippon Ganka Gakkai Zasshi. 2006;110(4):271-275.
6. Watanabe Y, Yuzawa Y, Mizumoto D, et al. Long-term follow-up study of 268 diabetic patients undergoing haemodialysis, with special attention to visual acuity and heterogeneity. Nephrol Dial Transplant. 1993;8(8):725-734. (Pubitemid 23237669)
7. Conway B, Fried L, Orchard T. Hemoglobin and overt nephropathy complications in type 1 diabetes. Ann Epidemiol. 2008;18(2):147-155.
8. Vekasi J, Marton Zs, Kesmarky G, Cser A, Russai A, Horvath B. Hemorheological alterations in patients with diabetic retinopathy. Clin Hemorheol Microcirc. 2001;24(1):59-64. (Pubitemid 32289949)
9. Trope GE, Lowe G, McArdle B, et al. Abnormal blood viscosity and haemostasis in long standing retinal vein occlusion. Br J Ophthalmol. 1983;67(3):137-142. (Pubitemid 13144009)
10. Piermarocchi S, Segato T, Bertoja H, et al. Branch retinal vein occlusion: the pathogenic role of blood viscosity. Ann Ophthalmol. 1990;22(8):303-311.
11. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353(8):782-792. (Pubitemid 41215487)
12. Orchard TJ, Dorman JS, Masser RE, et al. Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39(9):1116-1124. (Pubitemid 20263324)
13. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care. 1990;13(7):741-747. (Pubitemid 20207423)
14. National Institute of Health, Department of Health, Education and Welfare. 1978 Lipid Research Clinics Program. Washington, DC: US Government Printing Office; 1975. NIH publication 75-628.
15. Levey AS, Bosch J, Lewis B, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470.
16. Hypertension Detection and Follow-up Program Cooperative Group. The hypertension detection and follow-up program. Prev Med. 1976;5(2):207-215.
17. Lloyd CE, Klein R, Maser RE, Kuller LH, Becker DJ, Orchard TJ. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications. 1995;9(3):140-148.
18. Klein R, Klein B, Moss S, Cruickshanks K. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Opthalmol. 1998;105:1801-1815. (Pubitemid 28509717)
19. Ellis D, Buffone G. A new approach to the evaluation of proteinuric states. Clin Chem. 1977;23(4):660-670. (Pubitemid 8073594)
20. Harrell F. Survrisk.pak with %SPLINET MACRO. http://biostat.mc. vanderbilt.edu/twiki/pub/Main/SasMacros/survrisk.txt. Accessed July 16, 2008.
21. Nathan DM, Zinman B, Cleary PA, Backlund J-YC, Miller R, Orchard TJ. Modernday clinical course of type 1 diabetes mellitus: the DCCT/EDIC experience 1983-2008. Diabetologia. 2008;51(suppl 1):S50 Abstract 106.
22. Craig KJ, Williams J, Riley S, et al. Anaemia and diabetes in the absence of nephropathy. Diabetes Care. 2005;28(5):1118-1123.
23. Thomas M, MacIsaac R, Tsalamandris C, et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab. 2004;89(9):4359-4363.
24. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26(4):1164-1169. (Pubitemid 36929266)
25. Thomas S, Rampersad M. Anaemia in diabetes. Acta Diabetol. 2004;41(suppl 1):S13-S17.
26. Cusick M, Chew E, Hoogwerf B, et al; Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS): Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int. 2004;66(3):1173-1179.
27. Bosman D, Winkler A, Marsden J, Macdougall I, Watkins P. Erythropoietin deficiency anaemia is common in early diabetic nephropathy. Diabetes Care. 2001;24(3):495-499. (Pubitemid 32198419)
28. Fischer H, Schroeter W, Nauck M. Anemia in patients with type 1 and type 2 diabetes. Diabetes. 2005;54(suppl 1):A832.
29. Orchard T, Conway B. Are hemoglobin levels elevated in type 1 diabetes? Presented at: The 43rd Annual Meeting of the European Diabetes Epidemiology Group of the EASD; April 5-8, 2008; Lo-skolen Elsinore, Denmark.
30. Pichler G, Urlesberger B, Jirak P, et al. Reduced forearm blood flow in children and adolescents with type 1 diabetes (measured by near-infrared spectroscopy). Diabetes Care. 2004;27(8):1942-1946. (Pubitemid 38989236)
31. Krantz S, Jacobson L. Erythropoietin and the Regulation of Erythropoiesis. Chicago, IL: The University of Chicago Press; 1970.
32. Haffner SM, Klein R, Dunn JF, Moss SE, Klein BE. Increased testosterone in type 1 diabetic subjects with severe retinopathy. Opthalmol. 1990;97(10):1270-1274. (Pubitemid 20353970)
33. Haffner SM, Klein R, Dunn JE, Klein BE. Sex hormones and the incidence of severe retinopathy in male subjects with type 1 diabetes. Opthalmol. 1993;100(12):1782-1786. (Pubitemid 24004598)
34. Chaurasia RK, Singh R, Agrawal JK, Maurya OP. Sex hormones and diabetic retinopathy. Ann Ophthalmol. 1993;25(6):227-230.
35. Al-Khoury S, Afzali B, Thomas S. Diabetes, kidney disease, and anaemia: time to tackle a troublesome triad? Int J Clin Pract. 2007;61(2):281-289. (Pubitemid 46271291)
36. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa A. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr. 2000;159(8):627-628. (Pubitemid 30469453)
37. Brown MA, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS. 2006;10(2):143-149.
38. Takagi H, Watanabe D, Suzuma K, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2007;77(suppl 1):S62-S64. (Pubitemid 47212555)
39. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure? Am J Med Sci. 2007;334(4):260-264. (Pubitemid 351339284)
40. Drüeke T, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
41. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
42. Turczyński B, Michalska-Małecka K, Słowińska L, Szczesny S, Romaniuk W. Correlations between the severity of retinopathy in diabetic patients and whole blood and plasma viscosity. Clin Hemorheol Microcirc. 2003;29(2):129-137. (Pubitemid 37485509)
43. Little HL, Sacks AH. Role of abnormal blood rheology in the pathogenesis of diabetic retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 pt 1):522-534.
44. McMillan DE. Plasma protein changes, blood viscosity, and diabetic microangiopathy. Diabetes. 1976;25(suppl 2):858-864.
45. Lip PL, Blann AD, Jones AF, Lip GY. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye. 1998;12(pt 2):245-251.
46. Tong Z, Yang Z, Patel S, et al; Genetics of Diabetes and Diabetic Complication Study Group. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105(19):6998-7003.